Myovant Stock Analysis

MYOV -  USA Stock  

USD 20.73  0.32  1.52%

The latest Myovant Sciences price fall may encourage sophisticated investors to take a closer look at the firm as it is trading at a share price of 20.73 on 501,660 in trading volume. The company executives were unable to exploit market volatilities in May. However, diversifying your overall positions with Myovant Sciences can protect your principal portfolio during market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.01. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Myovant Sciences partners.
Additionally, see Stocks Correlation.

Search Stock Analysis 

 
Refresh
The Myovant Sciences stock analysis report makes it easy to digest most publicly released information about Myovant Sciences and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Myovant stock analysis module also helps to analyze the Myovant Sciences price relationship with some important fundamental indicators such as market cap and management efficiency.

Myovant Stock Analysis Notes

About 60.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 2.66. Myovant Sciences had not issued any dividends in recent years. Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd. Myovant Sciences operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 407 people. To find out more about Myovant Sciences contact the company at 44 20 7400 3351 or learn more at http://myovant.com.

Myovant Sciences Quarterly Cost of Revenue

301,000Share

Myovant Sciences Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Myovant Sciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Myovant Sciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Myovant Sciences generates negative expected return over the last 90 days
Myovant Sciences has high historical volatility and very poor performance
Myovant Sciences has a very high chance of going through financial distress in the upcoming years
Myovant Sciences has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 59.32 M. Net Loss for the year was (255.13 M) with loss before overhead, payroll, taxes, and interest of (79.36 M).
Myovant Sciences has a poor financial position based on the latest SEC disclosures
About 60.0% of the company outstanding shares are owned by corporate insiders
Latest headline from simplywall.st: Market Sentiment Around Loss-Making Myovant Sciences Ltd. - Simply Wall St

Myovant Sciences Upcoming and Recent Events

Earnings reports are used by Myovant Sciences to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Myovant Sciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of August 2021
Next Earnings Report11th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End10th of May 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Myovant Largest EPS Surprises

Earnings surprises can significantly impact Myovant Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2017-08-10
2017-06-30-0.29-0.39-0.134 
2016-11-21
2016-09-30-0.3467-0.45-0.103329 
2017-02-13
2016-12-31-0.2567-0.150.106741 
View All Earnings Estimates

Myovant Sciences SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Myovant Sciences prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Myovant Sciences investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Myovant Sciences specific information freely available to individual and institutional investors to make a timely investment decision.
4th of June 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
26th of May 2021
Other Events
View
19th of May 2021
Other Events
View
17th of May 2021
Unclassified Corporate Event
View
11th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
12th of February 2021
Unclassified Corporate Event
View
11th of February 2021
Financial Statements and Exhibits. Unclassified Corporate Event. Results of Operations and Financial Condition
View
4th of January 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Myovant Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Myovant Sciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Myovant Sciences backward and forwards among themselves. Myovant Sciences' institutional investor refers to the entity that pools money to purchase Myovant Sciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wellington Management Group LlpCommon Shares5.7 M116.4 M
Janus Henderson Group PlcCommon Shares5.2 M107.8 M
Bellevue Group AgCommon Shares5.2 M106.9 M
Pfm Health Sciences LpCommon Shares2.1 M42.3 M
Lord Abbett Co LlcCommon Shares1.8 M38 M
Susquehanna International Group LlpPut OptionsM20.8 M
Cormorant Asset Management LpCommon Shares1000 K20.6 M
Blackrock IncCommon Shares955.4 K19.7 M
Note, although Myovant Sciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Myovant Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Myovant Sciences's market, we take the total number of its shares issued and multiply it by Myovant Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Myovant Profitablity

Myovant Sciences' profitability indicators refer to fundamental financial ratios that showcase Myovant Sciences' ability to generate income relative to its revenue or operating costs. If, let's say, Myovant Sciences is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Myovant Sciences' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Myovant Sciences' profitability requires more research than a typical breakdown of Myovant Sciences' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.58) (0.63) 
Return on Average Equity 1.06  1.09 
Return on Invested Capital(1.38) (1.49) 
Return on Sales(3.71) (4.00) 

Management Efficiency

The entity has return on total asset (ROA) of (35.36) % which means that it has lost $35.36 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 20.67 %, meaning that it created $20.67 on every $100 dollars invested by stockholders. Myovant Sciences management efficiency ratios could be used to measure how well myovant sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Equity is likely to climb to 1.09 in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021. Myovant Sciences Total Assets are fairly stable at the moment as compared to the past year. Myovant Sciences reported Total Assets of 725.03 Million in 2020. Current Assets is likely to climb to about 760.3 M in 2021, whereas Return on Average Assets are likely to drop (0.63)  in 2021.
Last ReportedProjected for 2021
Book Value per Share(3.93) (4.03) 
Enterprise Value over EBIT(6.00) (6.47) 
Enterprise Value over EBITDA(6.12) (6.60) 
Price to Book Value(5.28) (5.42) 
Tangible Assets Book Value per Share 8.05  8.69 
Enterprise Value1.5 B1.4 B
Tangible Asset Value725 M782.3 M

Technical Drivers

As of the 20th of June, Myovant Sciences secures the mean deviation of 2.37, and Risk Adjusted Performance of (0.034018). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Myovant Sciences, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Myovant Sciences, which can be compared to its peers in the industry. Please verify Myovant Sciences standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Myovant Sciences is priced some-what accurately, providing market reflects its recent price of 20.73 per share. Given that Myovant Sciences has jensen alpha of (0.18), we recommend you to check Myovant Sciences's last-minute market performance to make sure the company can sustain itself at a future point.

Myovant Sciences Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Myovant Sciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myovant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myovant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Myovant Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arjona Ferreira Juan Camilo over two weeks ago via Macroaxis 
Exercise or conversion by Arjona Ferreira Juan Camilo of 1300 shares of Myovant Sciences subject to Rule 16b-3
Arjona Ferreira Juan Camilo over three weeks ago via Macroaxis 
Exercise or conversion by Arjona Ferreira Juan Camilo of 2867 shares of Myovant Sciences subject to Rule 16b-3
Merendino Lauren over two months ago via Macroaxis 
Acquisition by Merendino Lauren of 123300 shares of Myovant Sciences subject to Rule 16b-3
Merendino Lauren over two months ago via Macroaxis 
Myovant Sciences exotic insider transaction detected
Arjona Ferreira Juan Camilo over two months ago via Macroaxis 
Exercise or conversion by Arjona Ferreira Juan Camilo of 7000 shares of Myovant Sciences subject to Rule 16b-3
Matthew Lang over three months ago via Macroaxis 
Exercise or conversion by Matthew Lang of 30000 shares of Myovant Sciences subject to Rule 16b-3
Arjona Ferreira Juan Camilo over three months ago via Macroaxis 
Sale by Arjona Ferreira Juan Camilo of 1513 shares of Myovant Sciences
Frank Karbe over three months ago via Macroaxis 
Exercise or conversion by Frank Karbe of 750 shares of Myovant Sciences subject to Rule 16b-3
Frank Karbe over three months ago via Macroaxis 
Exercise or conversion by Frank Karbe of 300 shares of Myovant Sciences subject to Rule 16b-3
Marek David C over three months ago via Macroaxis 
Acquisition by Marek David C of 306427 shares of Myovant Sciences subject to Rule 16b-3
Marek David C over three months ago via Macroaxis 
Myovant Sciences exotic insider transaction detected
Lang Matthew over three months ago via Macroaxis 
Sale by Lang Matthew of 600 shares of Myovant Sciences

Myovant Sciences Technical and Predictive Indicators

Myovant Sciences Forecast Models

Myovant Sciences time-series forecasting models is one of many Myovant Sciences' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Myovant Sciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Myovant Sciences Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Myovant Sciences stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Myovant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Myovant Sciences. By using and applying Myovant Stock analysis, traders can create a robust methodology for identifying Myovant entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(3.67) (3.96) 
Gross Margin 0.90  0.89 
Profit Margin(3.87) (4.17) 
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womens health and endocrine diseases. The companys lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and womens health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Current Myovant Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Myovant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Myovant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
38.67Strong Buy3Odds
Myovant Sciences current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Myovant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Myovant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Myovant Sciences, talking to its executives and customers, or listening to Myovant conference calls.
Myovant Analyst Advice Details

Myovant Stock Analysis Indicators

Myovant Sciences stock analysis indicators help investors evaluate how Myovant Sciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Myovant Sciences shares will generate the highest return on investment. By understating and applying Myovant Sciences stock analysis, traders can identify Myovant Sciences position entry and exit signals to maximize returns.
Quick Ratio2.45
Fifty Two Week Low13.42
Shares Short Prior Month3.68M
Average Daily Volume Last 10 Day804.03k
Average Daily Volume In Three Month796.29k
Shares Percent Shares Out3.31%
Gross Margins-133.79%
Short Percent Of Float7.37%
Forward Price Earnings-16.19
Float Shares36.86M
Fifty Two Week High30.90
Enterprise Value To Ebitda-7.53
Fifty Day Average21.98
Two Hundred Day Average22.34
Enterprise Value To Revenue29.54
Additionally, see Stocks Correlation. Note that the Myovant Sciences information on this page should be used as a complementary analysis to other Myovant Sciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Myovant Sciences Stock analysis

When running Myovant Sciences price analysis, check to measure Myovant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Myovant Sciences is operating at the current time. Most of Myovant Sciences' value examination focuses on studying past and present price action to predict the probability of Myovant Sciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Myovant Sciences' price. Additionally, you may evaluate how the addition of Myovant Sciences to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Fund Screener
Find activelly-traded funds from around the world traded on over 30 global exchanges
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
The market value of Myovant Sciences is measured differently than its book value, which is the value of Myovant that is recorded on the company's balance sheet. Investors also form their own opinion of Myovant Sciences' value that differs from its market value or its book value, called intrinsic value, which is Myovant Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myovant Sciences' market value can be influenced by many factors that don't directly affect Myovant Sciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myovant Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Myovant Sciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myovant Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.